TY - JOUR T1 - Utility of Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of the Uterus JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 1185 LP - 1190 DO - 10.1097/IGC.0b013e3182229ad8 VL - 21 IS - 7 AU - Richard G. Moore AU - Craig Michael Miller AU - Amy K. Brown AU - Katina Robison AU - Margaret Steinhoff AU - Geralyn Lambert-Messerlian Y1 - 2011/10/01 UR - http://ijgc.bmj.com/content/21/7/1185.abstract N2 - Objective: The purpose of this pilot study was to determine whether the biomarker human epididymis protein 4 (HE4) correlates with depth of myometrial invasion, histologic grade, lymph vascular space invasion, positive cytologic washings, and nodal metastases in patients with endometrioid adenocarcinoma of the uterus.Methods: This was a prospective, observational study in women with biopsy-proven endometrioid adenocarcinoma. Concentrations of HE4 were assessed before surgery, and all surgical specimens were reviewed by dedicated gynecologic pathologists.Results: Included were a total of 96 women with endometrioid adenocarcinomas of the uterus, most (77%) with stage I disease. Levels of serum HE4 greater than 70 pM displayed a sensitivity of 94% and a negative predictive value of 97% in identifying stage IA (<50% myometrial invasion) versus stage IB (≥50% myometrial invasion) tumors and a sensitivity of 82% and negative predictive value of 82% versus all more advanced tumors.Conclusions: Human epididymis protein 4 may be a useful marker preoperatively in the clinical decision process for determining the need for lymph node dissection in women with endometrioid endometrial cancer. ER -